BlackRock Inc. Acquires Shares of 1,994,553 Tyme Technologies Inc (TYME)

BlackRock Inc. acquired a new position in shares of Tyme Technologies Inc (NASDAQ:TYME) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,994,553 shares of the company’s stock, valued at approximately $6,303,000. BlackRock Inc. owned 1.97% of Tyme Technologies at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TYME. Millennium Management LLC raised its stake in shares of Tyme Technologies by 551.5% in the 1st quarter. Millennium Management LLC now owns 1,551,315 shares of the company’s stock valued at $3,459,000 after purchasing an additional 1,313,190 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Tyme Technologies in the 2nd quarter valued at about $267,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Tyme Technologies in the 2nd quarter valued at about $248,000. Perkins Capital Management Inc. raised its stake in shares of Tyme Technologies by 330.0% in the 2nd quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock valued at $319,000 after purchasing an additional 77,550 shares during the period. Finally, Rhumbline Advisers acquired a new stake in shares of Tyme Technologies in the 2nd quarter valued at about $110,000. 11.14% of the stock is currently owned by institutional investors and hedge funds.

TYME opened at $2.13 on Friday. The stock has a market capitalization of $227.64 million, a price-to-earnings ratio of -10.14 and a beta of 0.57. Tyme Technologies Inc has a 1 year low of $2.01 and a 1 year high of $8.30.

TYME has been the topic of several recent research reports. BidaskClub downgraded Tyme Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, July 18th. Canaccord Genuity set a $10.00 price target on Tyme Technologies and gave the company a “buy” rating in a research note on Tuesday, July 31st. Zacks Investment Research raised Tyme Technologies from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Friday, August 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.50 price target on shares of Tyme Technologies in a research note on Thursday, October 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $7.44.

TRADEMARK VIOLATION NOTICE: “BlackRock Inc. Acquires Shares of 1,994,553 Tyme Technologies Inc (TYME)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2018/11/09/blackrock-inc-acquires-shares-of-1994553-tyme-technologies-inc-tyme.html.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding TYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyme Technologies Inc (NASDAQ:TYME).

Institutional Ownership by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply